Amryt Pharma plc (AMYT)

$6.8

-0.30 (-4.23%)
Rating:
Recommendation:
-
Symbol AMYT
Price $6.8
Beta 0.406
Volume Avg. 0.05M
Market Cap 436.404M
Shares () -
52 Week Range 5.61-12.45
1y Target Est -
DCF Unlevered AMYT DCF ->
DCF Levered AMYT LDCF ->
ROE -4.92% Neutral
ROA -2.14% Neutral
Operating Margin -
Debt / Equity 123.59% Buy
P/E 23.45 Strong Buy
P/B 1.28 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AMYT news


Dr. Joseph A. Wiley
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Global Select

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.